Category Archives: Buprenorphine

Acadia HealthCare Opioid Addiction Treatment

acadia-healthcareAcadia Healthcare is a leading behavioral healthcare services provider headquartered out of Franklin, Tennessee. The company was established in 2005 and has experienced rapid growth as a result of strategic acquisitions and a sharp focus on the delivery of psychiatric and chemical dependency treatment services.

Acadia recently bought out CRC Health Group for a reported $1.2 billion in a well-publicized sale which closed in February 2015. The acquisition significantly expanded Acadia’s opioid addiction treatment capabilities adding approximately 82 methadone/suboxone facilities nationwide. The company is nicely positioned to serve tens of thousands of patients on a daily basis who are struggling with opioid addiction and other associated illnesses. Methadone and buprenorphine products are utilized in association with a variety of counseling approaches.

Just added to Methadone.US are five of Acadia’s opioid treatment clinics located in San Diego, Riverside, Baltimore, Portland, and Southern Indiana.

Acadia’s mission statement:

Acadia Healthcare’s mission is to create behavioral health centers where people receive care that enables them to regain hope in a supportive, caring environment.

The company presently has behavioral healthcare facilities in 37 U.S. states, the United Kingdom, and Puerto Rico. These include residential treatment centers, inpatient psychiatric hospitals, outpatient clinics, and therapeutic school-based programs.

Right Path Clinics Offer Suboxone and Addiction Counseling

right-path-clinics-2Right Path is an opioid treatment provider operating in the greater Hampton Roads area of eastern Virginia. The organization specializes in the use of burprenorphine (the critical ingredient in Suboxone that alleviates opioid withdrawal symptoms).

Right Path currently have outpatient services in Virginia Beach, Newport News, and Suffolk, but plan to soon offer a location convenient for residents and visitors along the Outer Banks.

Recognizing the importance of individualized treatment plans, Right Path tailor their services to the needs of the individual patient. While suboxone is beneficial in eliminating the pain of opioid withdrawal, addiction counseling is essential in helping patients to understand the addiction and recovery process. Right Path provide addiction counseling as a component of their overall treatment program.

Evening and weekend hours are offered, and most insurance is accepted. The Right Path website has a helpful page that outlines various questions and issues that you might cover with your Suboxone Doctor in your first appointment. Their website provides another highly informative page on Suboxone which answers many common questions about this increasingly popular medication. More information on Right Path’s locations and contact information can be obtained here:

Maine’s Governor LePage May Undermine Opioid Addiction Treatment

Maine2Paul LePage, the governor of Maine, has announced that he is considering ceasing state-funded support for methadone. As an alternative, Maine is proposing that patients prescribed methadone be switched to a more affordable suboxone option as part of a $727,000 state budget cut. The story is here.

This is an indefensible decision with dire medical implications for opioid addicted patients currently receiving methadone. It equates to government officials making medical decisions that will negatively impact the health and well-being of thousands of people.

Representative Drew Gattine (a member of the Health & Human Services Committee) is quoted as saying the proposal shows a lack of understanding of the societal costs of addiction throughout the state of Maine.

Methadone and suboxone are both effective medications, but offer very unique characteristics and applications depending on the severity & chronicity of a patient’s opioid addiction. Buprenorphine (the actual opioid agonist contained in suboxone) has a much lower ceiling effect than does methadone meaning its effectiveness would be insufficient for a potentially large percentage of stable methadone patients on 60mg or more of methadone daily. Many patients on a moderate to high maintenance dose of methadone would not have their opioid withdrawal symptoms managed by even the maximum dosage allowed for suboxone – which is generally around 32 mg per day.

For a politician to, in essence, prescribe inappropriate medical treatment for a diagnosable medical condition is a huge state liability. The repercussions are alarming. Hopefully, the local medical establishment and other state officials will step in before irreversible damage is done. Methadone works. This cannot be denied.

Methadone has a long, proven track record of medical efficacy and cost effectiveness. Maine, in particular, has suffered in recent years with a severe opioid addiction epidemic. Reducing access to appropriate medical treatment like methadone will likely result in overdose deaths across Maine and an explosion of condemnation for the governor and his office.

Medication-assisted treatment (MAT) for opioid addiction is not a fad. It is scientifically proven effective and endorsed by multiple state & federal regulatory agencies as well as ASAM.

Buprenorphine and Liver Health

methadone-safe-for-liverJana Burson is a North Carolina physician who specializes in the treatment of opioid addiction using medications like buprenorphine and methadone. Dr. Burson is a passionate caregiver and patient advocate with considerable experience in the field of addiction treatment. She maintains an informative blog on the topic of opioid addiction treatment and recently posted her comments and observations on a revealing 2012 study.

The 2012 study by Saxon et al is reported in her blog to have followed more than 700 patients over 24 weeks who were receiving either methadone or buprenorphine (the active ingredient in Suboxone). These patients were checked for specific red flag elevations that would suggest emerging liver damage or liver inflammation. None of the patients receiving methadone or buprenorphine had significant abberations in liver functioning. This led the researchers to conclude that neither medication causes liver damage.

A 2014 follow-up study by Soyka and others (published in the American Journal on Addictions) found the same results in their research of 181 patients on Suboxone (buprenorphine + naloxone).

Studies like these help to dispel misinformation around opioid treatment medications and their safety. Dr. Burson expressed that it was once routine to order liver function tests for patients on buprenorphine therapy, but that this is likely unnecessary given the more recent research validating methadone and buprenorphine’s safety in regard to liver functioning.

There are addiction-related illnesses, like Hepatitis C, that can have highly detrimental effects on the liver. According to Dr. Burson, the Soyka study also showed that buprenorphine was not harmful even in patients diagnosed with Hepatitis C.

Thorough research studies like these are important in further legitimizing the benefits & established safety profile of opioid treatment medications. Having access to safe medications helps hundreds of thousands of people find effective treatment for chronic opioid addiction.

For More On Methadone

Methadone or Suboxone

addiction-is-treatable-2A common question among those seeking help is whether methadone or suboxone is the best choice for opioid replacement therapy. It reminds me of the age old debate … which is better, Ford or Chevy? Methadone has been used in opioid addiction treatment for about 45 years. Suboxone has been available to the public for 12 years. Each of these medications has been shown, through conclusive research, to be highly effective in eliminating opioid withdrawal. Both methadone and suboxone achieve a similar outcome, but with subtle differences. [view our comparison chart]

When opiate withdrawal symptoms are no longer a daily preoccupation and source of anxiety, individuals are free to invest their energy & time in productive, meaningful activities. Avoiding withdrawal sickness is the single greatest driver of continued opioid use, and often pushes an individual to desperate measures to maintain a supply of opiates so that they will not get sick.

People unfamiliar with addiction sometimes believe that an addicted person “just wants to get high”. To the contrary, most people with a chronic opioid addiction are just trying to get by, to get through the day without becoming sick all over again. Opioid withdrawal sickness is an exhausting roller coaster ride that rarely slows down long enough to allow an individual to escape. Their relief from opioid withdrawal sickness is typically short-lived, and they then begin feeling sick all over again. Quite a vicious cycle.

This is why suboxone (buprenorphine) and methadone are so valuable as a medical treatment for opioid addiction. These synthesized opioid replacement medications have a slow onset, long duration of action. This means that they don’t quickly spike to maximum levels in a person’s bloodstream like heroin. They reach maximum benefit several hours after they are taken. They then remain active in a person’s system for more than 24 hours and consequently keep painful withdrawal symptoms away. With no fear of being sick, a person can finally live their life and refocus their time where it needs to be: work, school, family, home, etc.

Methadone is a full opioid agonist whereas buprenorphine (the active ingredient in suboxone) is a partial opioid agonist. Because suboxone is a partial agonist, it is somewhat less susceptible to causing overdose and is considered easier to taper off of as individuals lower their daily dosage. As a result of methadone being a full opioid agonist, it is typically more effective with severe, long-term opioid addictions. Suboxone has a peak benefit at 24-32 mg per day whereby higher dosages than this will not produce additional withdrawal relief. However, methadone has no such “ceiling effect” and much higher dosages can be utilized as needed to eliminate a patient’s opioid withdrawal.

Welcome Access Recovery Solutions

ars-locationAccess Recovery Solutions (ARS) Delray Beach is a newly opened outpatient opioid treatment program that offers both methadone and buprenorphine. They are a member of Addiction Medical Solutions who have other methadone clinics across the country.

ARS specialize in medication assisted treatment and have a unique Maintenance to Abstinence program designed to assist patients in eventually becoming free of opioid medications once they have experienced a period of stability. The program is built on a two year continuum of care treatment model.

The ARS clinic provides individualized treatment planning for patients, and their counseling approaches include cognitive-behavioral and motivational approaches up to and including an intensive outpatient program (IOP). IOP is a SAMHSA endorsed, evidence-based addiction treatment that is in widespread use across the United States due to its effectiveness in helping patients learn about and apply effective recovery tools.

ARS offer a variety of other programs and services to serve the Delray Beach community including a Speakers Bureau. With advance notice, the company can provide speakers to educate professionals and non-professionals on substance use disorders and addiction issues. Interested parties can reach the organization at: 561-865-2550. The contact person for ARS Delray Beach is Mike Errico.

ars-delray-beach-florida